ArticlePharmaceuticals (Basel, Switzerland)2021
Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems.
Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Amorphous Solid Dispersions of Polyphenols: Current State of the Art (Part I).Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nano Engineered Chitosan-Based Delivery System for Vonoprazan Fumarate for Enhanced Bioavailability: Fabrication and Evaluation.International journal of nanomedicine · 2026Article
- Thermal Compatibility of New ACEI Derivatives with Popular Excipients Used to Produce Solid Pharmaceutical Formulations.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Intranasal Delivery of Carvedilol- and Quercetin-Encapsulated Cationic Nanoliposomes for Cardiovascular Targeting: Formulation andACS applied bio materials · 2024Article
- Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes.Drug delivery and translational research · 2024Article
- Chitosan-Based Hydrogels for Controlled Delivery of Asiaticoside-RichInternational journal of molecular sciences · 2023Article
- Synthesis and Characterization of Carvedilol-Etched Halloysite Nanotubes Composites with Enhanced Drug Solubility and Dissolution Rate.Molecules (Basel, Switzerland) · 2023Article
- Development of a Self-Assembled Hydrogels Based on Carboxymethyl Chitosan and Oxidized Hyaluronic Acid Containing Tanshinone Extract Nanocrystals for Enhanced Dissolution and Acne Treatment.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Solubilization and Controlled Release Strategy of Poorly Water-Soluble Drugs.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Chitosan as a Functional Carrier for the Local Delivery Anti-Inflammatory Systems ContainingPharmaceutics · 2022Article
- Progress in Research of Chitosan Chemical Modification Technologies and Their Applications.Marine drugs · 2022Review
- The Chitosan-Based System withPharmaceutics · 2022Article
- Amorphous Form of Carvedilol Phosphate-The Case of Divergent Properties.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with carvedilol (beta-blocker) to develop a formulation with a modified carvedilol release profile. As part of the research, six physical mixtures of chitosan with carvedilol were obtained and identified by spectral (PXRD, FT-IR, and Raman), thermal (DSC), and microscopic (SEM) methods. The next stage of the research estimated the profile changes and the dissolution rate for carvedilol in the obtained drug delivery systems; the reference sample was pure carvedilol. The studies were conducted at pH = 1.2 and 6.8, simulating the gastrointestinal tract conditions. Quantitative changes of carvedilol were determined using the developed isocratic UHPLC-DAD method. Established apparent permeability coefficients proved the changes in carvedilol's permeability after introducing a drug delivery system through membranes simulating the gastrointestinal tract and skin walls. A bioadhesive potential of carvedilol-chitosan systems was confirmed using the in vitro model. The conducted research and the obtained results indicate a significant potential of using chitosan as an excipient in modern oral or epidermal drug delivery systems of carvedilol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.